EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play

Core Insights - Enlivex Therapeutics Ltd. announced a private investment in public equity (PIPE) of 212 million shares at $1.00 per share, representing an 11.5% premium from the previous closing price, expecting gross proceeds of approximately $212 million [1] - The proceeds will be used to implement the first RAIN prediction markets token treasury strategy while maintaining focus on core business operations [2] - Enlivex aims to become the first U.S.-traded public company providing investors exposure to prediction markets following the transaction [4] Financial Details - The PIPE transaction involves 212 million shares priced at $1.00 each, totaling around $212 million in gross proceeds [1] - The funding will be a combination of USD and USDT [1] Business Strategy - Enlivex will utilize the PIPE proceeds to support the RAIN protocol, a decentralized predictions and options platform built on the Arbitrum network [2][3] - RAIN allows users to create and trade custom options on any market, governed by the RAIN token with a deflationary Buyback & Burn mechanism [3] Clinical Development - Enlivex is focused on the late-stage clinical development of Allocetra, a therapy for osteoarthritis, which affects over 32.5 million Americans and more than 300 million people globally [5] - Recent data from the Phase 2a trial of Allocetra showed significant pain reduction and functional improvement in patients with moderate to severe knee osteoarthritis at 6 months [6] Trial Results - Allocetra demonstrated a statistically significant improvement in pain and function at 3 months and 6 months in patients aged 60 and above, with reductions of -26.8 points and -27.8 points respectively compared to placebo [7]